Studies for Recurrent Lung Cancer
PF-00299804 vs. Erlotinib for Advanced Non-Small Cell Lung Cancer (UW1108)
A Randomized, Double-Blind Phase 3 Study Of PF-00299804, A Pan-Her Inhibitor, Vs. Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy
Investigator: Renato G. Martins, MD, MPH; Conditions: Non-Small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01360554
A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer
Investigator: Shilpen Patel, MD; Conditions: Lung Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01411098
Phase III Lucanix™ Vaccine Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Following Front-Line Chemotherapy (STOP)
Investigator: Keith Eaton, MD, PhD; Conditions: Lung Neoplasm, Carcinoma, Non-Small-Cell Lung: Stage IIIA (T3,N2 Only), Carcinoma, Non-Small-Cell Lung: Stage IIIB, Carcinoma, Non-Small-Cell Lung: Stage IV; Status: Recruiting; Study ID: NCT00676507
A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Investigator: Keith Eaton, MD; Conditions: NSCLC; Status: Recruiting; Study ID: NCT01221077
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel (Taxol)/OSI- 774(Erlotinib (Tarceva); NSC-718781) or OSI-774 Alone in Advanced Non-Small Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected By Serum Proteomics
Investigator: Fred Appelbaum, MD; Conditions: Lung Cancer; Status: Recruiting; Study ID: NCT00661193
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma; Status: Recruiting; Study ID: NCT00729664
A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)
Investigator: Fred Appelbaum, MD; Conditions: Lung Cancer; Status: Recruiting; Study ID: NCT00828139
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Investigator: Laura Chow, MD; Conditions: Tumors Characterized by Genetic Abnormalities of ALK; Status: Recruiting; Study ID: NCT01283516
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Gemcitabine + Cisplatin or Carboplatin as First-line Treatment for Patients With Stage IIIb or IV Squamous Non-small Cell Lung Cancer (NSCLC)
Investigator: Keith D. Eaton, MD; Conditions: Non-Small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01519804